Literatur
-
1
Abdulgany-Hamadeh M.
Tuberculosis and pregnancy.
Chest.
1992;
101
1114-1120
-
2
Acocella G, Nonis A, Perna G, Patane E, Gildroni-Grassi G, Grassi C.
Comparative bioavailability of isoniazid, rifampicin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study.
Am Rev Respir Dis.
1988;
138
886-890
-
3
Alzeer A H, FitzGerald J M.
Corticosteroids and tuberculosis: risks and use as adjunct therapy.
Tuber Lung Dis.
1993;
74
6-11
-
4
American Thoracic Society .
Diagnosis and treatment of disease caused by nontuberculous mycobacteria.
Am Rev Respir Dis.
1990;
142
940-953
-
5
American Thoracic Society .
Treatment of tuberculosis and tuberculosis infection in adults and children.
Am J Respir Crit Care Med.
1994;
149
1359-1374
-
6
Anonymous .
Tuberculosis in patients having dialysis.
Br Med J.
1980;
1
349
-
7
Aquinas M, Allan W G, Horsfall P A, Jenkins P K:, Hung-Yan W ,. et al .
Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong.
Br Med J.
1972;
i (803)
765-771
-
8
Avachat M K, Rambhau D, Rao V V, Rao B R, Rao J V.
Chronopharmacokinetics of Rifampicin.
Indian J Physiol Pharm.
1992;
36
251-254
-
9 Bartmann K. Antituberculosis drugs. Berlin, Heidelberg, New York: Springer Verlag 1988
-
10
Bartmann K, Radenbach K L, Zierski M.
Wandlungen in den Auffassungen und der Durchführung der antituberkulösen Chemotherapie.
Prax Klin Pneumol.
1985;
39
397-420
-
11
Bergstermann H, Rüchardt A.
Ciprofloxacin once daily versus twice daily for the treatment of pulmonary tuberculosis.
Infection.
1997;
25
227-232
-
12
British Thoracic Society Research Committee .
Six month versus nine month chemotherapy for tuberculosis of lymph nodes: preliminary results.
Respir Med.
1992;
86
15-19
-
13
British Thoracic Society .
A controlled trial of 6-month chemotherapy in pulmonary tuberculosis. First report: results during treatment.
Br J Dis Chest.
1981;
75
141-153
-
14
British Thoracic Society .
A controlled trial of 6-month chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond.
Br J Dis Chest.
1984;
78
330-336
-
15
Bruguerolle B.
Chronopharmacokinetics - Current Status.
Clin Pharmacokinet.
1998;
35
83-94
-
16
Campbell I A, Ormerod L P, Friend J AR.
Six month versus nine month chemotherapy for tuberculosis of lymph nodes: final results.
Respir Med.
1993;
87
621-623
-
17
Centers for Disease Control and Prevention .
Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.
Morb Mortal Wkly Rep.
1996;
45
921-925
-
18
Centers for Disease Control and Prevention .
Initial therapy for tuberculosis in the area of multi-drug-resistance.
Morb Mortal Wkly Rep.
1993;
42
1-8
-
19
Centers for Disease Control and P revention.
Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations.
Morb Mortal Wkly Rep.
1998;
47 (RR-20)
1-58
-
20
China Tuberculosis Control Collaboration .
Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis.
Lancet.
1996;
347
358-362
-
21
Citron K M, Thomas G O.
Ocular toxicity from ethambutol.
Thorax.
1986;
41
737-739
-
22
Cole S T, Telenti A.
Drug resistance in Mycobacterium tuberculosis.
Eur Respir J Suppl.
1995;
20
701s-713s
-
23
Combs D L, O’Brien R J, Geiter L J.
USPHS Tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability.
Ann Intern Med.
1990;
112
397-406
-
24
Crofton J.
Drug treatment of tuberculosis. Standard chemotherapy.
Br Med J.
1960;
2
370-373
-
25 Crofton J, Chaulet P, Maher D ,. et al .Guidelines for the management of drug-resistant tuberculosis. Publication no. WHO/GTB/96.210 World Health Organization, Geneva 1997
-
26
Dandapat M C, Mishra B M, Dash S P, Kar P K.
Peripheral lymph node tuberculosis: a review of 80 cases.
Br J Surg.
1990;
77
911-912
-
27
David H L.
Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis.
Appl Microbiol.
1970;
20
810-814
-
28
Davidson P T.
Managing tuberculosis during pregnancy.
Lancet.
1995;
346
199-200
-
29
Davies P DO.
The clinical efficacy of rifabutin in the treatment of pulmonary tuberculosis.
Rev Contemp Pharmacother.
1995;
6
121-127
-
30
Davies P DO.
Tuberculosis in the elderly.
J Antimicrobiol Chemother.
1994;
34 Suppl
A93-A100
-
31
CDC .
Updated guidelines for the use of rifabutin or rifampicin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleosid reverse transcriptase inhibitors (notice to readers).
MMWR.
2000;
49
185-188
-
32 Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose. 26. Informationsbericht Berlin Frankfurt/Main: pmi Verlag AG 2000
-
33
Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose: Richtlinien zur Chemotherapie der Tuberkulose.
Pneumologie.
1995;
49
217-225
-
34
Dickinson J M, Mitchison D A.
Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis.
Am Rev Respir Dis.
1981;
123
367-371
-
35
Donald P R, Seifart H I.
Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis.
J Pediatr.
1989;
115
483-486
-
36 Donald P R, Isaacs D. Tuberculosis in children. In: Clinical Tuberculosis. Davies PDO ed London: Chapman & Hall Medical 1998: 205-222
-
37
Dutt A K, Moers D, Stead W W.
Short course chemotherapy for extrapulmonary tuberculosis.
Ann Intern Med.
1986;
107
7-12
-
38
East and Central African and British Medical Research Council .
Clinical controlled trial of four short-course regimens of chemotherapy (three six-month, and one eight month) for pulmonary tuberculosis.
Tubercle.
1983;
64
153-166
-
39
Edwards O M, Courtney-Evans R J, Galley J M,. et al .
Changes in cortisol metabolism following rifampicin therapy.
Lancet.
1974;
2 (7880)
548-551
-
40
Ellard G G.
Chemotherapy of tuberculosis for patients with renal impairment.
Nephron.
1993;
64
169-181
-
41 Enarson D A, Rieder H L, Arnadottir T, Trébucq A. Management of tuberculosis. A guide for low income countries - 5th ed. Paris: International Union Against Tuberculosis and Lung Disease 2000
-
42
Feldman C.
Tuberculosis in the intensive care unit.
Eur Respir Mon.
1997;
4
195-214
-
43
Ferrer J.
Pleural tuberculosis.
Eur Respir J.
1997;
10
942-947
-
44
Fox W, Ellard G A, Mitchison D A.
Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946 - 1986, with relevant subsequent publications.
Int J Tuberc Lung Dis.
1999;
3 (suppl 2)
S231-279
-
45
Frieden T R, Sterling T, Pablos-Mendez A, Kilburn J O, Cauthen G M, Dooley S W.
The emergence of drug-resistant tuberculosis in New York City.
N Engl J Med.
1993;
328
521-526
-
46 Gesetz zur Verhütung und Bekämpfung von Infektionskrankheiten beim Menschen (Infektionsschutzgesetz IfSG) vom 20. Juli 2000. Bundesgesetzblatt (2000) Teil I, Nr. 33
-
47 Gilbert D N, Moellering R C, Sande M A. Sanford Guide to Antimicrobical Therapy 2001. Antimicrobical Therapy, Hyde Park S84
-
48
Gillespie S H, Kennedy N.
Fluoroquinolones: a new treatment for tuberculosis?.
Int J Tuberc Lung Dis.
1998;
2
265-271
-
49 Global Tuberculosis Programme. Treatment of tuberculosis: guidelines for national programmes. 2nd ed. Publication no. WHO/TB/97.220 Geneva: World Health Organization 1997: 1-66
-
50
Gonzalez-Montaner L J, Natal S, Yongchaiyud P, Olliaro P.
The Rifabutin Study Group: Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin.
Tubercle and Lung Disease.
1994;
75
341-347
-
51
Grange G M, Winstanley P A, Davies P DO.
Clinically significant drug interactions with antituberculosis drugs.
Drug Safety.
1994;
11
242-251
-
52
Grosser H, Loddenkemper R.
Verläufe schwerster Lungentuberkulosen unter intensivmedizinischer Therapie.
Öff Gesundh-Wes.
1985;
47
551-554
-
53
Grosset J, Leventis S.
Adverse effects for rifampin.
Rev Infect Dis.
1983;
5 (Suppl 3)
440
-
54
Havlir D V, Barnes P F.
Tuberculosis in patients with human immunodeficiency virus infection.
N Engl J Med.
1999;
340
367-373
-
55
Heifets L B.
Antimycobacterial drugs.
Semin Respir Infect.
1994;
9
84-103
-
56
Hong Kong Chest Service Tuberculosis Research Centre, Madras, British Medical Research Council .
A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong.
Am Rev Respir Dis.
1991;
143
262-267
-
57
Humphries M.
The management of tuberculous meningitis.
Thorax.
1992;
47
577-581
-
58
Iseman M D.
Treatment of multidrug-resistant tuberculosis.
N Engl J Med.
1993;
329
784-791
-
59
Jindani A, Aber V R, Edwards E A, Mitchison D A.
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Am Rev Respir Dis.
1980;
121
939-941
-
60
Joint Committee of the British Thoracic Society .
Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998.
Thorax.
1998;
53
536-548
-
61
Kennedy N, Berger L, Curram J, Fox R, Gutmann J, Kisyombe G M, Ngowi F I, Ramsay A R, Saruni A O, Sam N. et al .
Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.
Clin Infect Dis.
1996;
22
827-833
-
62
Kennedy N, Fox R, Kisyombe G M, Saruni A OS, Uiso L O, Ramsey A RC, Ngowi F I, Gillespie S H.
Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.
Am Rev Respir Dis.
1993;
148
1547-1551
-
63 Konietzko N, Loddenkemper R ( Hrsg). Tuberkulose. Stuttgart: Thieme Verlag 1999
-
64 Magdorf K, von der Hardt H. Tuberkulose. In Pädiatrische Pneumologie, Hrsg Rieger C, von der Hardt H, Sennhauser FH, Wahn U, Zach M Springer Verlag 1999: 839-875
-
65
Mahmoudi A, Iseman M D.
Surgical intervention in the treatment of drug resistant tuberculosis: update and extended follow up.
Am Rev Respir Dis.
1992;
145
A 816
-
66
Matz J, Borish L C, Routes J M, Rosenwasser L J.
Oral desensitization to rifampin and ethambutol in mycobacterial disease.
Am J Respir Crit Care Med.
1994;
149
815-817
-
67 McClatchy J H. Antimycobacterial drugs: mechanism of action, drug resistance, susceptibility testing and assays of activity in bacteriologic fluids. In: Lorian VE, ed. Antibiotics in laboratory medicine Baltimore: Williams & Wilkins 1986: 161-227
-
68
McMaster P, Isaacs D.
Critical review of evidence for short course therapy for tuberculous adenitis in children.
Pediatr Infect Dis.
2000;
19
401-404
-
69
Medical Research Council Working Party on Tuberculosis of the Spine .
Controlled trial of short-course regimens of chemotherapy in ambulatory treatment of spinal tuberculosis.
J Bone Joint Surg.
1993;
75
240-248
-
70
Medical Research Council .
Five-year assessment of controlled trials of short-course chemotherapy regimens of 6, 9, or 18 months’ duration for spinal tuberculosis in patients ambulatory from the start or undergoing radical surgery. Fourteenth report of the Medical Research Council Working Party on Tuberculosis of the Spine.
Intern Orthopaedics.
1999;
23
73-81
-
71
Migliori G B, Raviglione M C, Schaberg T, Davies P DO, Zellweger J P, Grzemska M, Mihaescu T, Clancy L, Casali L, and the Working Group of E RS, WHO, and I UATLD.
Tuberculosis management in Europe.
Eur Respir J.
1999;
14
978-992
-
72
Mitchison D A.
Basic mechanisms of chemotherapy.
Chest.
1980;
76
771-781
-
73
Mitchison D A.
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
Int J Tuberc Lung Dis.
1998;
2
10-15
-
74
Mitchison D A.
Pyrazinamide in the chemoprophylaxis of tuberculosis.
Am Rev Respir Dis.
1990;
142
1467
-
75
Mitchison D A.
The action of antituberculosis drugs during short-course chemotherapy.
Tubercle.
1985;
66
219-225
-
76
Mitchison D A, Nunn A J.
Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
Am Rev Respir Dis.
1986;
133
423-430
-
77
Mohanty K C, Dhamgaye T M.
Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis.
Chest.
1993;
104
1194-1198
-
78
Moore R D, Chaulk C P, Griffiths R ,. et al .
Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis.
Am J Respir Crit Care Med.
1996;
154
1013-1019
-
79
Moulding T, Dutt A K, Reichman L B.
Fixed-dose combinations of antituberculous medications to prevent drug resistance.
Ann Intern Med.
1995;
122
951-954
-
80
Musser J M.
Antimicrobial agent resistance in mycobacteria: molecular genetic insights.
Clin Microbiol Rev.
1995;
8
496-514
-
81
Muthuswamy P, Hu T C, Carasso B, Antonio M, Dandamudi N.
Prednisone as adjunctive therapy in the management of pulmonary tuberculosis.
Chest.
1995;
107
1621-1630
-
82
Nadler J P, Berger J, Nord J A, Cofsky R, Saxena M.
Amoxicillin/clavulanic acid for treating drug-resistant M. tuberculosis.
Chest.
1991;
99
1025-1026
-
83
Narita M, Askin D, Hollender E S, Pitchenik A E.
Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.
Am J Respir Crit Care Med.
1998;
158
157-161
-
84
Ormerod L P.
Chemotherapy of tuberculosis.
Eur Respir Mon.
1997;
4
273-297
-
85
Ormerod L P, Skinner C, Wales J M.
Hepatotoxicity of antituberculosis drugs.
Thorax.
1996;
51
111-113
-
86 Pablos-Méndez A, Laszlo A, Bustreo F ,. et al .Anti-tuberculosis drug resistance in the world. Publication WHO/GTP/97.229 Geneva: WHO Global Tuberculosis Programme 1997
-
87
Pablos-Méndez A, Raviglione M C, Laszlo A, Binkin N, Rieder H L, Bustreo F, Cohn D L.
Global surveillance for antituberculosis-drug resistance, 1994 - 1997.
N Engl J Med.
1998;
338
1641-1649
-
88
Pantel A M, McKeon J.
Avoidance and management of adverse reactions to antituberculosis drugs.
Drug Safety.
1995;
12
1-25
-
89
Radenbach D, Nowak D, Magnussen H.
Die Chemotherapie der Lungentuberkulose - Prinzipien, Therapiestudien, Konsequenzen für die Praxis.
Prax Klin Pneumol.
1988;
42
778-786
-
90
Raju B, Schluger N W.
Tuberculosis and pregnancy.
Sem Respir Crit Care Med.
1998;
19
298-305
-
91 Rieder H L, Chonde T M, Myking H, Urbanczik R, Laszlo A, Kim S J,. et al .The public health service national tuberculosis reference laboratory and the national laboratory network. Minimal requirements, role and operation in a low-income country. Paris: International Union Against Tuberculosis and Lung Disease 1998
-
92
Rizzi A, Rocco G, Robustellini M, Rossi G, Delala Pona C, Marssera F.
Results of surgical management of tuberculosis: experience in 206 patients undergoing operation.
Ann Thorac Surg.
1995;
59
896-900
-
93 Rote Liste 2001. Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Rote Liste Service GmbH Frankfurt/Main (Hrsg). Editio Cantor Verlag Aulendorf 2001
-
94
Schaberg T, Rebhan K, Lode H.
Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
Eur Respir J.
1996;
9
2026-2030
-
95 Schaberg T, Stahlmann R, Lode H. Therapie der Tuberkulose. Steinen: Zett-Verlag 2000: 62-133
-
96
Scheinmann P, Refabert L, Delacourt C, Le Bourgeois M, Paupe J, de Blic J.
Paediatric tuberculosis.
Eur Respir Mon.
1997;
4
144-174
-
97
Schoerman J F, Van Zyl L E, Laubscher J, Donald P R.
Effects of corticosteroids on intracranial pressure, computed tomography findings, and clinical outcome in young children with tuberculous meningitis.
Pediatrics.
1997;
99
226-231
-
98
Serke M, Hauer B, Loddenkemper R.
Chemotherapie bei Knochen- und Gelenktuberkulose.
Orthopäde.
1999;
28
375-380
-
99
Singapore Tuberculosis Service and British Medical Research Council .
Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis.
Am Rev Respir Dis.
1985;
132
374-388
-
100
Singapore Tuberculosis Service and British Medical Research Council .
Five-year follow-up of a clinical trial of three 6-month regimens of chemotheray given intermittently in the continuation phase in the treatment of pulmonary tuberculosis.
Am Rev Respir Dis.
1988;
137
1147-1150
-
101
Singapore Tuberculosis Service and British Medical Research Council .
Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis.
Am Rev Respir Dis.
1991;
143
707-712
-
102
Singapore Tuberculosis Service and British Medical Research Council .
Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months.
Tubercle.
1981;
62
95-102
-
103
Sirgel F A, Botha F JJ, Parkin D P, Van De Wal B W, Donald P R, Clark P K, Mitchinson D A.
The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment.
J Antimicrob Chemother.
1993;
32
867-875
-
104
Small P M, Schecter G F, Goodman P C, Sande M A, Chaisson R E, Hopewell P C.
Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.
N Engl J Med.
1991;
324
289-294
-
105
Snider Jr D E, Graczyk J, Bek E, Rogowski J.
Supervised six-month treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.
Am Rev Respir Dis.
1984;
130
1091-1094
-
106
Snider Jr D E, Layde P M, Johnson M W, Lyle M A.
Treatment of tuberculosis during pregnancy.
Am Rev Repir Dis.
1980;
122
65-79
-
107
Snider Jr D E, Powell K E.
Should women taking antituberculous drugs breast-feed?.
Arch Intern Med.
1984;
144
589-590
-
108
Steele M A, Burk R F, DesPrez R M.
Toxic hepatitis with isoniazid and rifampin.
Chest.
1991;
99
465-471
-
109
Strang J IG, Gibson D G, Mitchison D A, Girling D J, Kakaza H HS, Allen B W,. et al .
Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericarditis effusion in Transkei.
Lancet.
1988;
342
759-764
-
110
Strang J IG, Gibson D G, Nunn A J, Girling D J, Kakaza H HS, Fox W.
Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei.
Lancet.
1987;
2
1418-1422
-
111
Teo S K.
Assessment of a combined preparation of isoniazid, rifampicin, and pyrazinamide in the initial phase of chemotherapy in three 6-month regimens for smear positive pulmonary tuberculosis: a five-year follow-up report.
Int J Tuberc Lung Dis.
1999;
3
126-132
-
112
Thompson N P, Caplin M E, Hamilton M I, Gillespie S H, Clarke S W, Burroughs A K.
McIntyre N. Anti-tuberculous medication and the liver: dangers and recommendations in management.
Eur Respir J.
1995;
8
1384-1388
-
113
Urbanczik R.
Tuberkulosetherapie bei Patienten mit Niereninsuffizienz, Dialyse und nach Nierentransplantation.
Prax Klin Pneumol.
1983;
37
436-441
-
114
Van den Brande P, Van Steenbergen W, Vervoort G, Demedts M.
Ageing and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.
Am J Respir Crit Care Med.
1995;
152
1705-1708
-
115
Van Rie A, Warren R, Richardson M, Gie R P, Enarson D A, Beyers N, Van Helen P D.
Classification of drug-resistant tuberculosis in an epidemic area.
Lancet.
2000;
356
22-25
-
116
Vareldzis B, Grosset J, de Kantor J, Crofton J, Laszlo A, Felten M, Raviglione M C.
Drug-resistant tuberculosis: laboratory issues.
Tuber Lung Dis.
1994;
75
1-4
-
117
Veen J, Raviglione M, Rieder H L, Migliori G B, Graf P, Grzemka M, Zalesky R.
Standardized tuberculosis treatment outcome monitoring in Europe.
Eur Respir J.
1998;
12
505-510
-
118
Vernon A, Burman W, Benator D, Khan A, Bozeman L.
Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid.
Lancet.
1999;
353
1843-1847
-
119
Weis S E, Slocum P C, Blais F X, King B, Nunn M, Matney G B, Gomez E, Foresman B H.
The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis.
N Engl J Med.
1994;
330
1179-1184
-
120 Winstanley P A. Clinical pharmacology of antituberculosis drugs. In: Clinical Tuberculosis. Davies PDO ed London: Chapman & Hall Medical 1998: 225-242
-
121 World Health Organization .Tuberculosis programme: framework for effective tuberculosis control. Publication WHO/TB/94.179 Geneva: World Health Organization 1994
-
122 World Health Organization/International Union against Tuberculosis and Lung Disease .Anti-tuberculosis drug resistance in the world. Rep No. 2 Prevalence and trends WHO/CDS/TB/2000.278
-
123
Wyser C, Walzl G, Smedema J P, Swart F, van Schalkwyk E M, van de Wal B W.
Corticosteroids in the treatment of tuberculous pleurisy.
Chest.
1996;
110
333-338
-
124
Yuen A PW, Wong S HW, Tam C M, Chan S L, Wei W I, Lau S K.
Six month versus nine month chemotherapy for tuberculosis of lymph nodes: final results.
Otolaryngol Head Neck Surg.
1997;
116
189-192
Deutsches Zentralkomitee zur Bekämpfung der TuberkuloseGeneralsekretär Prof. Dr. Robert Loddenkemper
Lungenklinik Heckeshorn
Zum Heckeshorn 33
14109 Berlin
Email: loddheck@zedat.fu-berlin.de
